Compare Amylx Pharmaceuticals Inc (AMLX) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Harley-Davidson Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Harley-Davidson Inc trades at $25.14 (market cap $2.65B). The key difference: Harley-Davidson Inc is the larger of the two by market cap, and Harley-Davidson Inc pays a 2.92% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HOG | |
|---|---|---|
Market Cap | $1.98B | $2.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $31.03 |
52-Week Low | $7.64 | $17.19 |
Enterprise Value | $1.70B | $3.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Harley-Davidson (HOG) trades at $25.14, up 1.17% today, with a neutral technical outlook and mixed earnings history. The company reported Q1 2026 EPS of $0.22, missing estimates, but Q2 2026 results are due July 23, 2026. Recent news highlights production shifts back to the U.S. and cost-cutting initiatives. Valuation ratios appear attractive with a P/E of 13.03 and P/B of 0.86, though revenue has declined from $5.8B in 2023 to $4.5B in 2025.
The stock faces headwinds from declining revenue and margin pressure, but cost reductions and strategic shifts under new CEO Artie Starrs offer turnaround potential. Analyst consensus is cautious with a $23.20 price target below current levels. Key risks include competitive pressures and execution challenges. The upcoming Q2 earnings will be critical for confirming demand recovery and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
